AI startup Iambic on Monday announced a multi-year technology and discovery collaboration agreement with Takeda ...

After sharing word that it would be prioritizing artificial intelligence to aid discovery work, Takeda Pharmaceuticals has inked a multiyear deal to access Iambic Therapeutics' broad suite of& | ...

Explore AI in drug discovery and its journey from promise to proof in 2025 with significant achievements and challenges faced.

By Kamal Choudhury Feb 9 (Reuters) - Privately held Iambic said on Monday it has entered a multi-year partnership worth more ...

Takeda Pharmaceutical will apply Iambic Therapeutics’ artificial intelligence (AI)-based technologies and wet lab capabilities to design and develop small molecule drugs through a multi-year tech and ...

Iambic’s AI-platform includes Enchant, a multimodal transformer model designed to predict both preclinical and clinical endpoints, alongside NeuralPLexer. 1 Enchant recently received Nvidia HGX B200 ...

Read more about Artificial intelligence could change future of antimicrobial drug discovery: Here's why on Devdiscourse ...

Researchers from The Ohio State University and the Indian Institute of Technology Madras have developed an artificial intelligence framework to rapidly generate drug-like molecules that are easier to ...

Drug discovery requires two separate steps: checking whether a drug can bind to a harmful molecule or its receptor, and ...

There’s no doubt that large language models and generative AI tools have taken the world by storm. Their ability to create, ...

As China's new drug R&D enters the 'deep waters' of homogeneous competition, the path for followers has become increasingly ...